BRIEF REPORT: TELAPREVIR EXPERIENCE FROM TURKEY

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

KOMUR SUHEYLA; KURTARAN BEHICE; INAL AYSE SEZA; PULLUKCU HUSNU; ULU ASLIHAN; KUSCU FERIT; YAMAZHAN TANSU; TASOVA YESIM; ZEKI AKSU HASAN SALIH

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Hepatitis Monthly Year:2015 | Volume:15 | Issue:2 Page(s): 0-0

Download Full-Text

View:

347

Download:

156

Cites:

Information Journal Paper

Title

BRIEF REPORT: TELAPREVIR EXPERIENCE FROM TURKEY

Author(s)

Keywords

GENOTYPE 1

HEPATITIS C

TELAPREVIR

TURKEY

Abstract

Background: In patients with chronic HEPATITIS C, triple drug regimens containing a protease inhibitor, peginterferon and ribavirin were found to significantly increase sustained virologic response rates compared to dual drug regimen containing pegylated interferon and ribavirin, especially in GENOTYPE 1.Objectives: In TURKEY, TELAPREVIR has been used since March 2013. We aimed to evaluate results of patients with chronic HEPATITIS C treated with TELAPREVIR, peginterferon and ribavirin.Patients and Methods: We evaluated 28 patients with GENOTYPE 1 chronic HEPATITIS C infection treated with triple drug regimen containing TELAPREVIR, in three medical centers in TURKEY, retrospectively. Demographic data of patients, treatment indications, adverse events and outcomes were recorded.Results: Of 28 patients intended to treat, 25 (89.2%) patients completed the treatment. Overall, 21 (82.1%) patients had relapse and five patients were non-responder. Regarding the treatment outcomes of TELAPREVIR based regimen, 20/26 patients achieved sustained virological response. Pruritus, rash, dysgeusia, anorectal discomfort and anemia were main adverse effects. Blood transfusion and ribavirin dose reduction required for 7 and 11 patients, respectively. Due to several adverse effects, 10 patients were hospitalized.Conclusions: Although more frequent and severe adverse effects, TELAPREVIR has been promising for patients with treatment-experienced HEPATITIS C.

Cites

No record.

References

No record.

Cite

APA: Copy

KOMUR, SUHEYLA, KURTARAN, BEHICE, INAL, AYSE SEZA, PULLUKCU, HUSNU, ULU, ASLIHAN, KUSCU, FERIT, YAMAZHAN, TANSU, TASOVA, YESIM, & ZEKI AKSU, HASAN SALIH. (2015). BRIEF REPORT: TELAPREVIR EXPERIENCE FROM TURKEY. HEPATITIS MONTHLY, 15(2), 0-0. SID. https://sid.ir/paper/306894/en

Vancouver: Copy

KOMUR SUHEYLA, KURTARAN BEHICE, INAL AYSE SEZA, PULLUKCU HUSNU, ULU ASLIHAN, KUSCU FERIT, YAMAZHAN TANSU, TASOVA YESIM, ZEKI AKSU HASAN SALIH. BRIEF REPORT: TELAPREVIR EXPERIENCE FROM TURKEY. HEPATITIS MONTHLY[Internet]. 2015;15(2):0-0. Available from: https://sid.ir/paper/306894/en

IEEE: Copy

SUHEYLA KOMUR, BEHICE KURTARAN, AYSE SEZA INAL, HUSNU PULLUKCU, ASLIHAN ULU, FERIT KUSCU, TANSU YAMAZHAN, YESIM TASOVA, and HASAN SALIH ZEKI AKSU, “BRIEF REPORT: TELAPREVIR EXPERIENCE FROM TURKEY,” HEPATITIS MONTHLY, vol. 15, no. 2, pp. 0–0, 2015, [Online]. Available: https://sid.ir/paper/306894/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops